Open Daily: 10am - 10pm | Alley door pickup 10am - 7pm 3038 Hennepin Ave Minneapolis, MN
612-822-4611

  • Open Daily: 10am - 10pm
    Alley-side Pickup: 10am - 7pm

    3038 Hennepin Ave Minneapolis, MN
    612-822-4611

Open Daily: 10am - 10pm | Alley-side Pickup: 10am - 7pm
3038 Hennepin Ave Minneapolis, MN
612-822-4611
Metformin and Rosiglitazone: A Novel Therapy for Type 2 Diabetes

Metformin and Rosiglitazone: A Novel Therapy for Type 2 Diabetes

Okungbowa, Michael Awo

Paperback

Medical Reference

ISBN10: 6202094176
ISBN13: 9786202094177
Publisher: Lap Lambert Academic Pub
Published: Oct 29 2019
Pages: 80
Weight: 0.28
Height: 0.19 Width: 6.00 Depth: 9.00
Language: English
Diabetes induced hyperglycemia contributes to coagulation activation and hypofibrinolysis, resulting in a procoagulant state that predisposes patients to thrombotic events. Long-term hyperglycemia activates thrombotic factors. This review aims at understanding the mechanisms by which diabetes affects the coagulation pathway. The effects of improved glycemic control on coagulation and fibrinolysis in type 2 diabetes has been demonstrated for different oral antidiabetic therapies, such as, metformin in combination with rosiglitazone. Understanding the mechanism by which diabetes influences the coagulation pathway will help to develop more treatment strategies to reduce thrombotic events. A must read by Physicians, Clinicians and Care Givers to diabetics.

Also in

Medical Reference

View All